GE eyes another strong quarter as booming engine demand and solid defense orders fuel optimism for a Q3 earnings beat.

HON moves forward with the Solstice spin-off, setting Oct. 30, 2025, as the date for its debut as an independent advanced materials company.

RADNOR, Pa. , Oct. 17, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Molina Healthcare, Inc. ("Molina") (NYSE: MOH) on behalf of those who purchased or otherwise acquired Molina securities between February 5, 2025, and July 23, 2025, inclusive (the "Class Period").

Automaker Stellantis and Chinese autonomous vehicle company Pony.ai have signed a non-binding agreement to build robotaxis for deployment in Europe.

Wedbush analysts believe IMAX Corp (NYSE:IMAX) warrants a premium valuation, given what they called the “trifecta” of upcoming filmed-for-IMAX (FFI) titles across geographies, global footprint and margin expansion. In a note to clients on Friday, the analysts wrote that they expect the company will be poised to surpass peak earnings before interest, taxes, depreciation, and amortization (EBITDA) margins in the next two years.

Indisputably, so-called “neo-cloud” stocks have been some of the most impressive performers of 2025. This generally describes companies providing artificial intelligence (AI)-specific cloud infrastructure, particularly emerging firms like Nebius NASDAQ: NBIS and CoreWeave NASDAQ: CRWV.

MMM readies its Q3 results with steady gains in key segments and a positive earnings signal hinting at another potential beat.

New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-month price target of $4.00, representing over 80% upside from the Company's recent closing price of $2.20. The initiation report highlights Immuron's proprietary polyclonal antibody platform, strong revenue growth from its over-the-counter product Travelan®, and an expanding clinical pipeline addressing major global infectious diseases.

GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.

CRDO's new ZeroFlap optical transceivers and cutting-edge DSPs fuel rapid growth across AI, cloud and data center markets.

BJ's Restaurants (BJRI) remains undervalued despite recent stock declines, with strong margin improvements and promising innovations like the pizza platform revamp. BJRI's Q2 FY 2025 saw best-in-three-years margins, accelerated traffic, and cautious guidance, but market overreacted to softer outlook and slower new restaurant openings. The pizza platform overhaul and continued margin expansion could drive incremental traffic, higher average checks, and significant free cash flow for expansion or buybacks.

Yahoo Finance executive editor Brian Sozzi breaks down the latest market moves for October 17, 2025. Stocks bounced back following Thursday's sell-off that was sparked by concerns over regional banks and fraudulent loan activity.

The SPDR® S&P Regional Banking ETF offers diversified exposure to U.S. regional banks, reflecting sector health via an equal-weighted approach. Recent volatility in the KRE ETF stems from credit risk events at Zions Bancorporation and Western Alliance, but broader credit conditions remain stable according to S&P Global. Monetary policy has turned dovish, with falling yields and Fed rate cuts providing a tailwind for KRE and improving its valuation.

Erie Indemnity shares have underperformed, falling 31% in the past year despite revenue and premium growth. ERIE posted Q2 EPS of $3.34 and revenue of $1.06B, with higher management fees but rising operational costs and a cybersecurity incident. The company maintains strong policy retention and premium growth, but faces weather-related losses and a high short interest.

TSCDY, GO and ABBNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 17, 2025.

P&G (PG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

General Dynamics (GD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

First Hawaiian (FHB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flagstar Financial (FLG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

British American Tobacco (BTI) no longer offers compelling long-term growth, prompting a full exit after strong capital gains. BTI's New Categories segment underperformed expectations, widening the gap with Philip Morris (PM), which leads in smokeless products innovation. BTI's capital allocation choices, such as increased buybacks over growth investment, signal short-term focus and limit organic revenue prospects.